Showing results (451-460 of 661) with videos related to
Sort By:
Pageof 67
The British Journal of Radiology|January 25, 2002
The influence of different technique factors on image quality of chest radiographs as evaluated by modified CEC image quality criteriaB Lanhede, M Båth, S Kheddache, et al.Proteomics|September 16, 2003
Mitochondrial proteome: altered cytochrome c oxidase subunit levels in prostate cancerPaul C Herrmann, John W Gillespie, Lu Charboneau, et al.The American Journal of Cardiology|January 15, 1990
Hemodynamic and renal effects of atrial natriuretic peptide in congestive heart failureM A Fifer, C R Molina, A C Quiroz, et al.Circulation|June 12, 2002
Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: : Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-upMarco Roffi, David J Moliterno, Bernhard Meier, et al.Journal of the American College of Cardiology|May 21, 2016
Impact of Ejection Fraction and Aortic Valve Gradient on Outcomes of Transcatheter Aortic Valve ReplacementSuzanne J Baron, Suzanne V Arnold, Howard C Herrmann, et al.Journal of Cardiac Surgery|August 18, 2009
Late surgical mitral valve repair after percutaneous repair with the MitraClip systemJason H Rogers, Khung Keong Yeo, John D Carroll, et al.JACC. Cardiovascular Interventions|October 24, 2009
Benefit of facilitated percutaneous coronary intervention in high-risk ST-segment elevation myocardial infarction patients presenting to nonpercutaneous coronary intervention hospitalsHoward C Herrmann, Jiandong Lu, Bruce R Brodie, et al.Journal of the American College of Cardiology|September 19, 2003
Angiographic variables predict increased risk for adverse ischemic events after coronary stenting with glycoprotein IIb/IIIa inhibition: results from the TARGET trialMitchell J Ross, Howard C Herrmann, David J Moliterno, et al.Journal of the American College of Cardiology|March 1, 1996
Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplastyD J Kereiakes, N S Kleiman, J Ambrose, et al.Diabetologia|April 14, 2010
Association of glucose metabolism with diastolic function along the diabetic continuumR Stahrenberg, F Edelmann, M Mende, et al.Pageof 67